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Abstract: Clozapine is an atypical antipsychotic, that is established as the treatment of choice
for treatment-resistant schizophrenia (SCZ). To date, no study investigating comprehensive DNA
methylation changes in SCZ patients treated with chronic clozapine has been reported. The purpose
of the present study is to reveal the effects of clozapine on DNA methylation in treatment-resistant
SCZ. We conducted a genome-wide DNA methylation profiling in peripheral leukocytes (485,764 CpG
dinucleotides) from treatment-resistant SCZ patients treated with clozapine (n = 21) in a longitudinal
study. Significant changes in DNA methylation were observed at 29,134 sites after one year of
treatment with clozapine, and these genes were enriched for “cell substrate adhesion” and “cell matrix
adhesion” gene ontology (GO) terms. Furthermore, DNA methylation changes in the CREBBP (CREB
binding protein) gene were significantly correlated with the clinical improvements. Our findings
provide insights into the action of clozapine in treatment-resistant SCZ.
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1. Introduction
Schizophrenia (SCZ) is a mental disorder characterized by symptoms that include delusions,
hallucinations, and disorganized speech [1]. Approximately, 30% of SCZ patients are
treatment-resistant [2], and the atypical antipsychotic clozapine has become the treatment of choice
in this setting [3,4]. Recently, we have demonstrated that cell adhesion molecules, which play an
important role in brain development including in axonal/dendrite growth, synapse formation and
plasticity [5], were potential candidates for the molecular basis of clozapine response by conducting
gene expression profiling using induced pluripotent stem (iPS) cell-based technology [6]. However,
the molecular and epigenetic mechanisms underlying the therapeutic efficacy of clozapine have not
yet been fully elucidated.
DNA methylation is an epigenetic modification that plays a critical role in brain function [7,8].
DNA methylation mainly occurs at the 5′ position of the cytosine base followed by a guanine base that
is called CpG [9]. A number of studies have demonstrated aberrant DNA methylation in SCZ [10–18].
Furthermore, growing evidence suggests that DNA methylation may be involved in the therapeutic
efficacy of atypical antipsychotic drugs [19–24]. With respect to clozapine, two animal studies
have demonstrated that acute clozapine treatment induces DNA demethylation in the promoters
of specific GABAergic and glutamatergic genes [25,26]. However, to our knowledge, no study
investigating comprehensive DNA methylation changes in SCZ patients treated with chronic clozapine
has been reported.
In the present study, we comprehensively analyzed changes in DNA methylation in peripheral
leukocytes from treatment-resistant SCZ patients treated with clozapine in a longitudinal study.
Next, we examined the correlation between changes in DNA methylation in response to clozapine and
clinical improvements in treatment-resistant SCZ.
2. Results
2.1. Changes in DNA Methylation in Leukocytes after Clozapine Treatment
Of the 350,142 CpG sites analyzed, significant changes in DNA methylation were observed
at 29,134 sites when we compared samples from 21 patients collected before and after one year
of treatment with clozapine. The top 100 CpG sites are shown in Supplementary Table 1. Of the
29,134 CpG sites showing significant differences in methylation, clozapine treatment increased DNA
methylation at 13,052 sites (44.8%) and decreased DNA methylation at 16,082 sites (55.2%).
Classification of significant CpG sites based on their locations within genes revealed that 11,850
sites (40.7%) were located in promoter regions; 9479 sites (32.5%) were in gene bodies; 864 sites (3.0%)
were in 3′-UTRs; the remainders were found in intergenic regions. Decreases in DNA methylation
following clozapine treatment were more likely to occur in promoter regions than in other regions
(60.5% in promoter regions vs. 51.6% in other regions; Fisher’s exact test p = 7.00 × 10−16; Figure 1).
Classification of CpG sites based on location relative to CpG content in the genes (CpG island (CGI),
CGI shore, CGI shelf, and others) revealed that 7656 sites (26.3%) were located within CGIs; 7334
sites (25.2%) were in CGI shores; and 2846 sites (9.8%) were in CGI shelves. Sites of decreased DNA
methylation following clozapine treatment were more likely to occur in CGI regions than in other
regions (66.9% in CGI regions versus 51.0% in other regions; Fisher’s exact test p = 3.83 × 10−36;
Figure 1). Interestingly, significant CpG sites of decreased DNA methylation which were located in
CGIs in promoter regions include several GABA, glutamate, and related SCZ susceptibility genes [27],
such as GAD1 (glutamate decarboxylase 1), GRIN2A (glutamate ionotropic receptor NMDA type
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subunit 2A), GRIN2D (glutamate ionotropic receptor NMDA type subunit 2D), and GRM7 (glutamate
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Figure 1. The proportions of CpG sites which showed increased or decreased DNA methylation 
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29,134 significant CpG sites, 11,850 sites (40.7%) were located in the promoter regions (increased 
DNA methylation: 39.5%, decreased DNA methylation: 60.5%), 9479 sites (32.5%) in gene bodies 
(increased DNA methylation: 49.1%, decreased DNA methylation: 50.9%), and 864 sites (3.0%) in 
3′-UTRs (increased DNA methylation: 47.5%, decreased DNA methylation: 52.5%). Of 29,134 CpG 
sites, 7656 sites (26.3%) were located in the CGIs (CpG island) (increased DNA methylation: 33.1%, 
decreased DNA methylation: 66.9%), 7334 sites (25.2%) in CGI shores (increased DNA methylation: 
40.3%, decreased DNA methylation: 59.7%), and 2846 sites (9.8%) in CGI shelves (increased DNA 
methylation: 55.9%, decreased DNA methylation: 44.1%). 
A list of the CpG sites located in promoter regions with average DNA methylation differences 
(Δβ) greater than 0.05 and paired t-test p-values less than 0.001 is shown in Table 1. Two of these 
CpG sites are located in the TRIM15 (tripartite motif containing 15) gene, which has been implicated 
in SCZ (Figure 2) [28]. Additionally, gene ontology (GO) analysis revealed that genes with DNA 
methylation changes following clozapine treatment were enriched for the “cell substrate adhesion” 
and “cell matrix adhesion” GO terms (False discovery rate (FDR) q < 0.05). 
 
 
Figure 2. DNA methylation changes following clozapine treatment in the TRIM15 gene. Clozapine 
caused increased DNA methylation changes at two CpG sites (cg02772121 and cg12422154) in the 
promoter region of the TRIM15 gene (p = 3.2 × 10−4, and p = 2.5 × 10−4, respectively). 
Figure 1. The proportions of CpG sites which showed increased or decreased DNA methylation
changes after clozapine treatment. Of 29,134 significant CpG sites, clozapine caused an increased
DNA methylation at 13,052 sites (44.8%) and decreased DNA methylation at 16,082 sites (55.2%).
Of 29,134 significan CpG sites, 11,850 sites (40.7%) were located in th promoter regions (increased
DNA methylation: 39.5%, decreased DNA m thylation: 60.5%), 9479 sites (32.5%) in gene bodies
(increased DNA methylation: 49.1%, decreased DNA methylation: 50.9%), and 864 sites (3.0%) in
3′-UTRs (increased DNA methylation: 47.5%, decreased DNA methylation: 52.5%). Of 29,134 CpG
sites, 7656 sites (26.3%) were located in the CGIs (CpG island) (increased DNA methylation: 33.1%,
decreased DNA methylation: 66.9%), 7334 sites (25.2%) in CGI shores (increased DNA methylation:
40.3%, decreased DNA methylation: 59.7%), and 2846 sites (9.8%) in CGI shelves (increased DNA
methylation: 55.9%, decreased DNA methylation: 44.1%).
A list of the CpG sites located in promoter regions with average DNA methylation differences
(∆β) greater than 0.05 and paired t-test p-values less than 0.001 is shown in Table 1. Two of these CpG
sites are located in the TRIM15 (tripartite motif containing 15) gene, which has been implicated in SCZ
(Figure 2) [28]. Additionally, gene ontology (GO) analysis revealed that genes with DNA methylation
changes following clozapine treatment were enriched for the “cell substrate adhesion” and “cell matrix
adhesion” GO terms (False discovery rate (FDR) q < 0.05).
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Figure 2. DNA methylation changes following clozapine treatment in the TRIM15 gene. Clozapine
caused increased DNA methylation changes at two CpG sites (cg02772121 and cg12422154) in the
promoter region of the TRIM15 gene (p = 3.2 × 10−4, and p = 2.5 × 10−4, respectively).
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Table 1. A list of the significant CpG sites with average ∆β > 0.05 and paired t-test p-value < 0.001 in the gene promoter regions. CGI, CpG island; UCSC, University of
California Santa Cruz; * Positions refer to Genome Research Consortium human genome build 37 (GRCh37/UCSC human genome 19 (hg19).
Probe ID
Average Beta
Difference before
Treatment of Clozapine
Average Beta
Difference after
Treatment of Clozapine
Average Beta
Difference between
Treatment of Clozapine
p-Value Chromosome Position *
UCSC
RefGene
Name
UCSC
RefGene
Group
Relation to
UCSC CpG
Island
cg15542713 0.427 0.496 0.070 1.1 × 10−4 1 42385581 HIVEP3 Promoter CGI shore
cg02772121 0.570 0.624 0.054 3.2 × 10−4 6 30130881 TRIM15 Promoter Others
cg10864200 0.608 0.557 −0.050 7.3 × 10−4 4 720809 PCGF3 Promoter CGI shelf
cg12422154 0.601 0.652 0.050 2.5 × 10−4 6 30130819 TRIM15 Promoter Others
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2.2. Correlations between Changes in DNA Methylation in Leukocytes and Clinical Outcomes
Analysis of correlations between changes in psychotic symptoms (% Positive and Negative
Syndrome Scale (PANSS)) and clinical variables (clozapine dose, duration of clozapine treatment,
age of onset, gender, and use of mood stabilizers) revealed no significant correlations (p > 0.05). Upon
analysis of correlations between ∆β-values for the 29,134 CpG sites showing significant changes in
DNA methylation after clozapine treatment and % PANSS, a CpG site associated with the CREBBP
(CREB binding protein) gene, cg05151055, was the only site that was significantly correlated with
changes in psychotic symptoms (FDR q < 0.05; Figure 3).
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forming tissue and neuronal connections crucial for nervous system development [31]. Animal studies
suggest that dysfunction of neuronal cell adhesion molecules, which are expressed primarily in the
central nervous system where they regulate synaptic signaling, may lead to impairment of memory
and learning [32,33]. Furthermore, pathways related to cell adhesion have been shown to contribute to
SCZ susceptibility in a genome-wide association study [34], and increased blood levels of neuronal cell
adhesion molecules have been observed in SCZ [35,36]. These results suggest that changes of neuronal
cell adhesion-related molecules may be implicated in the pathophysiology of SCZ, and clozapine may
exert its therapeutic effects by altering DNA methylation of genes encoding these molecules.
We found that increases in DNA methylation of the CREBBP gene following clozapine treatment
was significantly correlated with clinical improvements in treatment-resistant SCZ. This result
suggests that epigenetic modification of the CREBBP gene in peripheral leukocytes can predict clinical
responses to clozapine in treatment-resistant SCZ. CREBBP is a protein that possesses intrinsic histone
acetyltransferase activity, in addition to acting as a scaffold to stabilize protein interactions within the
transcription complex [37]. Pathway analyses of results from genome-wide association studies have
demonstrated that this gene is associated with SCZ [38,39]. Furthermore, CREBBP variants have been
associated not only with clinical symptoms, but also with cognitive phenotypes in SCZ [36,40].
Our study has several limitations that should be noted. First, our sample size was small, and
studies that replicate our findings in a larger cohort are needed. Second, patients enrolled in this
study had been treated with various kinds of antipsychotics prior to treatment with clozapine. Third,
the dosage and duration of clozapine treatment were not uniform across the patient cohort. Fourth, it is
unclear whether changes in DNA methylation following clozapine treatment are normalized to control
levels due to a lack of control data. Fifth, it is also unclear whether the DNA methylation changes
following the treatment are specific to clozapine or are common among other antipsychotics. Direct
comparisons to previous studies that examined the effects of antipsychotics on DNA methylation are
hampered by the use of different study designs and analysis of different tissues [19–24]. Further blood
studies using other antipsychotics are needed to reveal differences between clozapine and other
antipsychotics. Sixth, we did not investigate the relationship between DNA methylation and expression.
Further functional studies, including transcriptome analysis and cell adhesion assays, are required to
clarify the molecular mechanisms of clozapine action. Finally, it is important to note that the observed
changes in DNA methylation after clozapine treatment were analyzed only in peripheral leukocytes,
and studies in brain tissue are needed to confirm the mechanistic interpretation of our results.
4. Materials and Methods
4.1. Subjects
Twenty-one patients with SCZ (mean age: 42.1 ± 11.4 years; eight males and 13 females) were
recruited from Kochi, Tokushima, and Osaka University Hospitals in Japan. All subjects were of
Japanese origin and had been treated with various antipsychotic drugs before treatment with clozapine.
Peripheral blood was collected twice from each patient, just before introduction of clozapine and after
one year of treatment. The mean dose of clozapine was 473.8 ± 91.3 mg/day, and the mean duration of
clozapine treatment was 340.8 ± 182.7 days. The psychotic symptoms of the patients were evaluated
using PANSS at the time of peripheral blood sample collection. The mean PANSS score was 113.4 at
baseline and 91.7 at the end of treatment, respectively. The clinical characteristics of the patients are
summarized in Supplementary Table 2. SCZ was diagnosed according to DSM-IV criteria by at least
two expert psychiatrists on the basis of extensive clinical interviews and a review of medical records.
All patients met the criteria for treatment-resistant SCZ and clozapine administration, as described in
the clozapine drug information provided in Japan [41,42]. No psychiatric comorbidities were present
in any of the patients. The study protocol was approved by the institutional ethics committee of
Tokushima University Graduate School (Project ID, H28-1; Date of approval, 23 June 2016), and all
enrolled participants provided their signed, written, informed consent for participation.
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4.2. Analysis of DNA Methylation
Genomic DNA was extracted from peripheral blood using the QIAamp DNA Blood Mini Kit
(Qiagen, Germantown, MD, USA). Bisulfite conversion of 500 ng of genomic DNA was performed
with the EZ DNA methylation kit (Zymo Research, Irvine, CA, USA). DNA methylation levels were
assessed using Infinium® HumanMethylation450 BeadChips (Illumina Inc., San Diego, CA, USA),
which makes it possible to examine DNA methylation status at more than 485,000 CpG sites, according
to the manufacturer’s instructions, and the resulting data was analyzed using the methylation analysis
module within the BeadStudio software (Illumina Inc.). The DNA methylation status of CpG sites
(termed the β-value) was calculated based on the ratio of the signal from a methylated probe relative
to the sum of the signal from both methylated and unmethylated probes. β values ranged from 0
(completely unmethylated) to 1 (fully methylated). For intra-chip normalization of probe intensities,
colored balance and background corrections were performed for every set of 12 samples from the
same chip using internal control probes. CpG sites used for statistical analyses met the following
criteria: (1) β-values with detection p-values < 0.05; (2) autosomal CpGs, with no missing values in
any subjects; (3) no probe single nucleotide polymorphisms (SNPs) with minor allele frequencies
≥5% in the HapMap-JPT population; (4) no probe cross-reactivity; and (5) no SNPs at CpG sites and
single-base extension sites detailed in a previous paper [43]. The final data set for peripheral leukocytes
included 350,142 sites.
4.3. Statistical Analysis
A paired t-test was used to assess DNA methylation changes following clozapine treatment.
p-values < 0.05 were considered statistically significant. Gene ontology analysis was performed using
the Database for Annotation, Visualization, and Integrated Discovery (DAVID) [44]. An FDR correction
was applied at the 0.05 level for multiple comparisons. Pearson’s correlations were performed to assess
the effects of clinical variables, including clozapine dose, duration of clozapine treatment, age of onset,
gender, and use of mood stabilizers on PANSS percentage changes (% PANSS; defined as (PANSS at
the end of the study − PANSS at baseline)/PANSS at baseline). A univariate linear regression model
was used to examine the relationship between β-values for probes with significant DNA methylation
changes following clozapine treatment and % PANSS. An FDR correction was applied at the 0.05 level
for multiple comparisons.
5. Conclusions
We report a comprehensive analysis of DNA methylation changes in peripheral leukocytes from
patients with treatment-resistant SCZ following clozapine treatment. We found that genes with
clozapine-induced changes in DNA methylation were associated with cell substrate adhesion and cell
matrix adhesion. These results provide insight into potential mechanisms of action of clozapine in
treatment-resistant SCZ. Further functional studies are needed to clarify the molecular mechanisms of
clozapine action.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/3/632/s1.
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